Industry Research Partnerships
The Industry Discovery and Development Program (IDDP) aims to promote for-profit interest in JDRF’s mission to find a cure for type 1 diabetes (T1D) and its complications. JDRF IDDP funding is available to support research programs in companies or for-profit entities worldwide, either publicly or privately held, focused on a priority area within JDRF’s mission. IDDP provides a mechanism and opportunity for JDRF to foster long-term collaborative relationships with industry, taking promising T1D research through discovery and development and toward commercialization.
For more information about applying for an IDDP grant, please contact Olivia Lou, Ph.D., Director of External Scientific Partnerships, at olou@jdrf.org or 212-479-7606.
If you would also like to inquire with the JDRF T1D Fund, an independently managed venture philanthropy fund that makes early-stage commercial investments, please contact Maureen Suda, Head of Communications & Engagement, at msuda@t1dfund.org.
Current Partnerships
Our current portfolio includes the following industry partnerships:
Therapeutic Pipeline
JDRF funds life-changing T1D research, which is leading the way to better treatments, prevention and, one day, a world without T1D. These are the current portfolio partners:
Industry Partnerships
| Company | Description | Discovery/ Preclinical |
Clinical Trials |
|---|---|---|---|
Artificial Pancreas |
|||
| QuLab Medical Ltd. | Minimally-Invasive Dual CGM-CKM Patch | ||
| Ypsomed | Open-Protocol Insulin Pump | ||
Beta Cell Replacement |
|||
| Giner Inc. | Advanced Oxygen Generator for Oxygenated Cell Capsules | ||
| IVIVA | Vascularized Islet Transplant for the Treatment of T1D | ||
Prevention |
|||
| IBM | T1D Disease Modeling | ||
Completed Partnerships
Industry Partnerships
| Company | Description |
|---|---|
Artificial Pancreas |
|
| Animas Corporation + Dexcom | Development of a semi-closed-loop insulin delivery system utilizing the Animas insulin pump and Dexcom continuous glucose sensor |
| Arecor | Stable ultra-concentrated insulin compositions |
| AstraZeneca | Insulin/pramlintide combination for the treatment of T1D (NCT02500979, NCT01708044) |
| BD Diabetes Care | Insulin infusion partnership
Glucose binding protein based continuous glucose monitor (NCT01469715) Artificial pancreas system with advanced integrated CGM sensor and infusion set |
| BD Technologies | Understanding CSII-induced inflammation for the design of a robust extended wear continuous subcutaneous insulin infusion set |
| Cam Med | Evopump: The first truly bandage-like patch pump |
| Capillary Biomedical | CSII catheter with rapid on/off PK-PD, consistent PK-PD, and extended lifetime to 14 days |
| Dose Safety Company | Evaluation of FL controller during exercise and high CHO/high fat meals |
| EOFlow | Miniaturized wearable disposable artificial pancreas system that integrates a continuous glucose sensor and an insulin pump |
| GluSense | Prototype development and preclinical evaluation of an innovative cell based, implantable continuous glucose monitor (CGM) |
| Latitude Pharmaceuticals | Stabilized glucagon nanoemulsions |
| Medtronic | Orthogonally redundant glucose sensor |
| Pacific Diabetes Technologies | Accuracy of glucose sensing technologies (NCT03528174) |
| SFC Fluidics | Patch pump with open-protocol communication |
| Tandem | Dual drug infusion pump for insulin and pramlintide (Symlin®) |
| Thermalin | Ultra-rapid insulin analogs with shortened duration of signaling |
| Tidepool | Commercialization of Loop (NCT03838900) |
| Xeris Pharmaceuticals | Non-aqueous glucagon to enable outpatient studies with a bi-hormonal pump (NCT03424044) |
Beta Cell Regeneration |
|
| Aspect Biosystems Ltd. | Microfluidic-based 3D bioprinting technology for immune-protected implantable beta cell therapy |
| Biogen | Treatment with an Fn14 agonist as a potential approach to achieve islet cell reconstitution in T1D
TWEAK as a potential pancreatic regeneration factor |
| California Institute for Biomedical Rese | Calibr-JDRF translational academic research partnership |
| Develogen | Discovery and development of beta cell regeneration drugs for T1D |
| GNF Novartis | Discovering new biology and translating this knowledge into innovative treatments for T1D
Novel strategies for inducing antigen-specific immune tolerance in T1D Development of novel methods for beta cell selective delivery of therapeutic agents |
| Housey Pharmaceutical | Discovery and development of antidiabetic drugs |
| NGM Biopharmaceuticals | Discovery of novel gastrointestinal factors that enhance beta cell growth
Beta cell regeneration biologics discovery |
| Transition Therapeutics | Stimulation of islet cell regeneration in T1D with GLP-1 and gastrin |
Beta Cell Replacement |
|
| Athersys | Genome-wide discovery of pancreatic islet cell differentiation factors using MAPC adult stem cells |
| Beta-02 | Phase I, IIa with human islets (ßAir study) (NCT02064309) |
| Defymed | Allogenic preclinical validation of the bioartificial pancreas, MAILPAN® |
| ES Cell International | Isolation of clinically-compliant human embryonic stem cells |
| Frequency Therapeutics | Creation of human glucose-responsive, insulin-sensitive cells |
| Living Cell Technologies | An open-label investigation in New Zealand of the safety and effectiveness of DIABECELL® in patients with T1D (NCT00940173) |
| Lockheed Martin | Graphene composite membranes for nano-enabled macroencapsulation |
| Noveome Biotherapeutics | Differentiation of amnion-derived cells to clinically viable islets for transplantation |
| Plureon Corporation | Generation of pancreatic beta cells from pluripotent adult stem cells in human adipose tissue |
| Sanofi + Genzyme | Development partnership for T1D therapeutics development |
| Sernova | Cell Pouch Study (NCT03513939) |
| Ximerex | Islet transplantation into animal models using chimeric donor animals |
Complications |
|
| AGTC | Study of anti-neovascular genes for treatment of diabetic retinopathy |
| Genentech | Ranibizumab (Lucentis®) for edema of the macula in diabetes: A phase II study—the READ 2 study (NCT00407381)
Combined approach to treatment using ranibizumab (Lucentis®) and efalizumab for diabetic macular edema study: The CAPTURE study (NCT00676559) Ranibizumab (Lucentis®) for edema of the macula in diabetes: Protocol 3 with high dose—the READ 3 study (NCT01077401) |
| iCo Therapeutics | iCo-007 as monotherapy or in combination with ranibizumab (Lucentis®) in the treatment of diabetic macular edema (the iDEAL study) (NCT01565148) |
| KalVista | The development of intravitreal plasma kallikrein inhibitors (KDV001) for diabetic macular edema (DME) (NCT02193113) |
| Sangamo BioSciences | A phase II clinical trial of SB-509, a novel VEGF-activator, in patients with diabetic neuropathy (NCT00406458, NCT01079325) |
Glucose Control |
|
| Amylin Pharmaceuticals | Combined metreleptin and insulin therapy for T1D (NCT01268644) |
| Gubra | Glucose-responsive insulin linkers |
| Lexicon Pharmaceuticals | LX4211 (sotagliflozin) in T1D with high unmet need (NCT02383940) |
| Protomer Technologies | Development of glucose responsive insulin analogues with enhanced pharmacokinetics
Engineering and therapeutic optimization of glucose responsive insulins toward finalized candidates to preclinical development |
| SmartCells | Proof-of-concept for an injectable, glucose-regulated insulin for T1D (NCT02269735) |
| vTv Therapeutics | Adjunctive Insulin Therapy (TTP399) (NCT0333537) |
| Zucara Therapeutics | Preclinical drug development of somatostatin receptor 2 antagonists for the prevention of recurrent hypoglycemia in T1D |
Immune Therapies |
|
| Avidex | Monoclonal T cell receptor therapeutics in the treatment of T1D |
| Axxam | Identification of Kv1.3 blockers for the treatment of T1D
Discovery research of innovative immunosuppressant for prevention of T1D |
| Bayhill Therapeutics | Phase I clinical trial of BHT-3021, an antigen-specific immunotherapeutic DNA vaccine for T1D (NCT00453375) |
| EpiVax | T1D tolerance induction with natural regulatory T cell epitopes |
| Immunocore | A novel monoclonal T cell receptor therapeutic targeted towards a proprietary antigen associated with T1D |
| Just Biotherapeutics | Development of a bioequivalent alefacept (anti-CD2) through IND filing |
| MacroGenics | A phase II/III, randomized, double-blind study to evaluate efficacy and safety of teplizumab (MGA031), an anti-CD3 monoclonal antibody, in children and adults with recent-onset T1D (NCT00385697) |
| REGiMMUNE | Antigen-specific therapeutic RGI-3100 for T1D |
| SAB Biotherapeutics | |
| Selecta Biosciences | Diabetes antigen specific tolerance induction by targeted nanoparticles |
| TetraGenetics | Targeting antibodies to immune cells |
| Tolerx | Human clinical trials of TRX4 (otelixizumab), an anti-CD3 monoclonal antibody, in patients with T1D (NCT00451321, NCT00678886) |
Prevention |
|
| CoMentis | Proof-of-concept testing of GTS-21, a selective ±7-nAChR agonist, to prevent or delay the onset of T1D
Proof-of-concept testing of mecamylamine (ATG-003) as topical anti-angiogenic therapy in patients with diabetic macular edema (NCT00536692) |
| DiabetOmics | Point-of-care assays for detection of islet autoantibodies (Insudex) |
| IBM | T1D disease modeling expansion |
| Osiris Therapeutics | Prochymal for the treatment of patients with new onset T1D |
| Wave 80 Biosciences | Fast, inexpensive, tetraplex detection of T1D-associated autoantibodies by FRET |
Research News
The feed is either empty or unavailable.